Cone rod dystrophy is a rare inherited retinal disorder impacting cones and rods, leading to progressive vision loss. The market for cone rod dystrophy is poised for growth due to rising disease ...

The trial is a phase 1/2 open-label, ascending-dose study of the safety and efficacy of OPGx-LCA5. Recently, the company ...

Unfortunately, I have been diagnosed many years back with Retinal Dystrophy ( genetic mutation ). The condition has no ...

Emerging gene therapy administered through a one-time subretinal injection marks a major milestone for the inherited retinal ...

Opus Genetics (IRD) announced that the first participant has been dosed in the Company’s OPGx-BEST1 Phase 1/2 clinical trial for Best disease. Best disease, or vitelliform macular dystrophy, is a rare ...

MeiraGTx’s AAV-AIPL1 has already led to vision gains in blind children, as regulatory submissions for the gene therapy close ...

To date in the Phase 1/2 portion of the trial, six late-stage participants have been treated with OPGx-LCA5, and all six have experienced clinically meaningful improvements in vision, providing ...

A new approach to gene therapy for retinitis pigmentosa may help patients with advanced disease regain vision regardless of which genetic mutation is causing the condition. An optogenetic therapy ...

European Medicines Agency grants MCO-010 five Orphan designations across a wide spectrum of retinal diseases involving photoreceptor loss, including syndromic and non-syndromic, rod- and cone-dominant ...

Geographic atrophy (GA) is one of two kinds of advanced age-related macular degeneration (AMD). It’s an eye disease that damages cells in the central part of your retina called the macula. Late-stage ...

Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Inherited Retinal Dystrophies including Retinitis Pigmentosa Aldeyra Therapeutics, ...